SWEDISH MEDICAL CENTER
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1910-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.swedish.org/
Clinical Trials
40
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)โข Click on a phase to view related trials
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
- Conditions
- Central Line Associated Blood Stream Infections (CLABSI)
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 17800
- Registration Number
- NCT07108660
- Locations
- ๐บ๐ธ
Providence Alaska Medical Center, Anchorage, Alaska, United States
๐บ๐ธSt. Mary Medical Center, Apple Valley, California, United States
๐บ๐ธProvidence Saint Joseph Medical Center, Burbank, California, United States
Early Chest Tube Removal After Surgery for Primary Spontaneous Pneumothorax: A Randomized Controlled Trial
- Conditions
- Primary Spontaneous Pneumothorax
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT06411431
- Locations
- ๐บ๐ธ
Swedish Cancer Institute, Seattle, Washington, United States
Minimally Invasive Esophagectomy Pain Control Trial
- Conditions
- Postoperative ComplicationsPostoperative Pain, Acute
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05906134
- Locations
- ๐บ๐ธ
Swedish Cancer Institute, Seattle, Washington, United States
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- Drug: combinations of up to 3 FDA approved drugs from a panel of compounds
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT05380349
- Locations
- ๐บ๐ธ
Swedish Medical Center, Seattle, Washington, United States
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
- Conditions
- Covid19SARS-CoV Infection
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT04542993
- Locations
- ๐บ๐ธ
Swedish Medical Center, Seattle, Washington, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
Expanding Biologic Options Transform Treatment Landscape for Psoriatic Arthritis
Recent clinical trials demonstrate sustained efficacy of newer biologics like bimekizumab and risankizumab in treating psoriatic arthritis, expanding treatment options beyond traditional TNF inhibitors.
New Clinical Studies and Classification Criteria Advance Understanding of Axial PsA Treatment
Leading research reveals that axial inflammation affects up to 40% of psoriatic arthritis patients, prompting efforts to establish clearer diagnostic criteria based on clinical features, imaging findings, and genetic markers.